References
- Päivönsalo-Hietanen T, Tuominen J, Vaahtoranta-Lehtonen H, Saari KM. Incidence and prevalence of different uveitis entities in Finland. Acta Ophthalmol Scand. 1997;75(1):76–81. doi:https://doi.org/10.1111/j.1600-0420.1997.tb00255.x.
- Gritz DC, Wong IG. Incidence and prevalence of uveitis in Northern California; the Northern California epidemiology of uveitis study. Ophthalmology. 2004;111(3):491–500. discussion 500. doi:https://doi.org/10.1016/j.ophtha.2003.06.014.
- Tsirouki T, Dastiridou A, Symeonidis C, et al. A focus on the epidemiology of uveitis. Ocul Immunol Inflamm. 2018;26(1):2–16. doi:https://doi.org/10.1080/09273948.2016.1196713.
- Verhagen FH, Brouwer AH, Kuiper JJW, et al. Potential predictors of poor visual outcome in human leukocyte antigen-B27-associated uveitis. Am J Ophthalmol. 2016;165:179–187. doi:https://doi.org/10.1016/j.ajo.2016.02.024.
- Abásolo L, Á P-G, Díaz-Valle D, et al. Influence of baseline demographic and clinical characteristics in the visual outcome of intermediate uveitis: a survival analysis. Br J Ophthalmol. 2016;100(12):1651–1655.doi:https://doi.org/10.1136/bjophthalmol-2015-307774.
- Finger RP, Fimmers R, Holz FG, Scholl HPN. Prevalence and causes of registered blindness in the largest federal state of Germany. Br J Ophthalmol. 2011;95(8):1061–1067. doi:https://doi.org/10.1136/bjo.2010.194712.
- Frick KD, Drye LT, Kempen JH, et al. Associations among visual acuity and vision- and health-related quality of life among patients in the multicenter uveitis steroid treatment trial. Invest Ophthalmol Vis Sci. 2012;53(3):1169–1176.doi:https://doi.org/10.1167/iovs.11-8259.
- Jalil A, Yin K, Coyle L, Harper R, Jones NP. Vision-related quality of life and employment status in patients with uveitis of working age: a prospective study. Ocul Immunol Inflamm. 2012;20(4):262–265. doi:https://doi.org/10.3109/09273948.2012.684420.
- Tan P, Koh YT, Wong PY, Teoh SC. Evaluation of the impact of uveitis on visual-related quality of life. Ocul Immunol Inflamm. 2012;20(6):453–459. doi:https://doi.org/10.3109/09273948.2012.723781.
- Grajewski RS, Caramoy A, Frank KF, et al. Spectrum of uveitis in A German tertiary center: review of 474 consecutive patients. Ocul Immunol Inflamm. 2015;23(4):346–352.doi:https://doi.org/10.3109/09273948.2014.1002567.
- Barisani-Asenbauer T, Maca SM, Mejdoubi L, Emminger W, Machold K, Auer H. Uveitis- a rare disease often associated with systemic diseases and infections- a systematic review of 2619 patients. Orphanet J Rare Dis. 2012;7:57. doi:https://doi.org/10.1186/1750-1172-7-57.
- Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol. 2005;140:509–516.
- Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000;130(4):492–513. doi:https://doi.org/10.1016/S0002-9394(00)00659-0.
- Deuter C, Garweg J, Heiligenhaus A, Pleyer U, Tappeiner C Leitlinie Nr. 24b - Nichtinfektiöse Uveitis posterior. 2017. http://www.dog.org/wp-content/uploads/2009/2009/LL-2024b.pdf.pdf. Updated 2017.
- Joshi L, Talat L, Yaganti S, et al. Outcomes of changing immunosuppressive therapy after treatment failure in patients with noninfectious uveitis. Ophthalmology. 2014;121(5):1119–1124.doi:https://doi.org/10.1016/j.ophtha.2013.11.032.
- Abásolo L, Rosales Z, Díaz-Valle D. et al. Immunosuppressive drug discontinuation in noninfectious uveitis from real-life clinical practice: a survival analysis. Am J Ophthalmol. 2016;169:1–8. doi:https://doi.org/10.1016/j.ajo.2016.06.007.
- Mackensen F, Baydoun L, Garweg J, Heiligenhaus A, Hudde T. Uveitis intermedia. Ophthalmologe. 2014;111(11):1033–1040. doi:https://doi.org/10.1007/s00347-014-3198-6.
- Dick AD, Rosenbaum JT, Al-Dhibi HA, et al. Guidance on noncorticosteroid systemic immunomodulatory therapy in noninfectious uveitis: fundamentals of care for uveitis (FOCUS) initiative. Ophthalmology. 2018;125(5):757–773.doi:https://doi.org/10.1016/j.ophtha.2017.11.017.
- Rath A, Olry A, Dhombres F, Brandt MM, Urbero B, Ayme S. Representation of rare diseases in health information systems: the orphanet approach to serve a wide range of end users. Hum Mutat. 2012;33(5):803–808. doi:https://doi.org/10.1002/humu.22078.
- Heiligenhaus A, Niewerth M, Ganser G, Heinz C, Minden K. Prevalence and complications of uveitis in juvenile idiopathic arthritis in a population-based nation-wide study in Germany: suggested modification of the current screening guidelines. Rheumatology (Oxford). 2007;46(6):1015–1019. doi:https://doi.org/10.1093/rheumatology/kem053.
- Tappeiner C, Roesel M, Heinz C, Michels H, Ganser G, Heiligenhaus A. Limited value of cyclosporine A for the treatment of patients with uveitis associated with juvenile idiopathic arthritis. Eye. 2009;23(5):1192. doi:https://doi.org/10.1038/eye.2008.174.
- Müller D, Augustin M, Banik N, et al. Memorandum Register für die Versorgungsforschung. Das Gesundheitswes. 2010;72(11):824–839. doi:https://doi.org/10.1055/s-0030-1263132.
- Stausberg J, Maier B, Bestehorn K, et al. Memorandum Register für die Versorgungsforschung: update 2019. Das Gesundheitswes. 2020;82(3):e39–e66. doi:https://doi.org/10.1055/a-1083-6417.
- Tutz G, Schmid M. Modeling Discrete Time-to-event Data. Cham: Springer Springer series in statistics; 2016
- Denniston AK, Lee RW, Pavesio C, et al. Uveitis Dataset. 2018.
- Li J, Heinz C, Finger RP. Registerstudien in der Ophthalmologie [Registry-based research in ophthalmology]. Ophthalmologe. 2018 Oct;115(10):826-831. German. doi:https://doi.org/10.1007/s00347-018-0719-8. PMID: 29766264
- Askling J, Baecklund E, Granath F, et al. Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register. Ann Rheum Dis. 2009;68(5):648–653. doi:https://doi.org/10.1136/ard.2007.085852.
- Tappeiner C, Schenck S, Niewerth M, Heiligenhaus A, Minden K, Klotsche J. Impact of antiinflammatory treatment on the onset of uveitis in juvenile idiopathic arthritis: longitudinal analysis from a nationwide pediatric rheumatology database. Arthritis Care Res (Hoboken). 2016;68(1):46–54. doi:https://doi.org/10.1002/acr.22649.
- Minden K, Niewerth M, Zink A, et al. Long-term outcome of patients with JIA treated with etanercept, results of the biologic register JuMBO. Rheumatology. 2012;51(8):1407–1415. doi:https://doi.org/10.1093/rheumatology/kes019.
- Horneff G, Minden K, Foeldvari I, et al. Aktuelles aus dem BIKER-Register. Zeitschrift für Rheumatologie. 2014;73(10):897–906. doi:https://doi.org/10.1007/s00393-014-1397-9.
- Keane PA, Karampelas M, Sim DA, et al. Objective measurement of vitreous inflammation using optical coherence tomography. Ophthalmology. 2014;121(9):1706–1714. doi:https://doi.org/10.1016/j.ophtha.2014.03.006.
- Kim M, Kim H, Kwon HJ, Kim SS, Koh HJ, Lee SC. Choroidal thickness in Behcet’s uveitis: an enhanced depth imaging-optical coherence tomography and its association with angiographic changes. Invest Ophthalmol Vis Sci. 2013;54(9):6033–6039. doi:https://doi.org/10.1167/iovs.13-12231.
- Nakai K, Gomi F, Ikuno Y, et al. Choroidal observations in Vogt–Koyanagi–Harada disease using high-penetration optical coherence tomography. Graefes Arch Clin Exp Ophthalmol. 2012;250(7):1089–1095. doi:https://doi.org/10.1007/s00417-011-1910-7.
- Invernizzi A, Cozzi M, Staurenghi G. Optical coherence tomography and optical coherence tomography angiography in uveitis: a review. Clin Exp Ophthalmol. 2019;47(3):357–371. doi:https://doi.org/10.1111/ceo.13470.
- Pichi F, Sarraf D, Morara M, Mazumdar S, Neri P, Gupta V. Pearls and pitfalls of optical coherence tomography angiography in the multimodal evaluation of uveitis. J Ophthalmic Inflamm Infect. 2017;7(1):20. doi:https://doi.org/10.1186/s12348-017-0138-z.
- Marchese A, Agarwal A, Moretti AG, et al. Advances in imaging of uveitis. Ther Adv Ophthalmol. 2020;12:2515841420917781. doi:https://doi.org/10.1177/2515841420917781.